In the phase 1/2 INSPIRE DUCHENNE trial, interim data showed an average microdystrophin expression of 110% among participants with Duchenne muscular dystrophy (DMD) at 90 days post treatment ...

Duchenne muscular dystrophy represents a severe, progressive disease that affects 1 in 3,600–6,000 live male births. It is one of the most severe muscle diseases to affect children.

Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are the two most common forms of the disease, representing 80% of all cases of muscular dystrophy. Both diseases almost ...

Parent Project Muscular Dystrophy-led updates to community guidance seek to assist trial sponsors in the clinical development of safe and effective therapies for the treatment of Duchenne, Becker ...

Between one in 3,500 and one in 5,000 children are born with Duchenne or Becker muscular dystrophy, the most common forms of the disease, each year, according to the National Institutes of Health.

Becker Muscular Dystrophy, like Duchenne Muscular Dystrophy (DMD), is a progressive X-linked neuromuscular disorder that results in significant skeletal and cardiac muscle deterioration over time.

Becker Muscular Dystrophy, like Duchenne Muscular Dystrophy (DMD), is a progressive X-linked neuromuscular disorder that results in significant skeletal and cardiac muscle deterioration over time.

NEWPORT BEACH, Calif., June 18, 2021 /PRNewswire/ -- CureDuchenne, a leading global nonprofit focused on finding and funding a cure for Duchenne muscular dystrophy, announces the launch of ...

– Edgewise leadership to discuss these updates on Thursday, June 26 at 8:30 a.m. Eastern Time at a virtual investor event – BOULDER, Colo., June 26, 2025 /PRNewswire/ -- Edgewise Therapeutics ...

U.S. FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s focus in neuromuscular diseases Capricor remains on track for the ...